A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Figures and Tables
Published: 17 March 2021| Version 1 | DOI: 10.17632/b6sct48jmb.1
Contributor:
Brett KingDescription
Supplementary Figures 1-7. Supplementary Tables 1-5
Files
Categories
Alopecia Areata, Janus Kinase